Refine
H-BRS Bibliography
- yes (20) (remove)
Departments, institutes and facilities
- Fachbereich Angewandte Naturwissenschaften (20) (remove)
Document Type
- Article (18)
- Part of a Book (1)
- Conference Object (1)
Year of publication
- 2006 (20) (remove)
Keywords
- insulin resistance (3)
- CD21 (2)
- cardiovascular disease (2)
- pioglitazone (2)
- thiazolidinediones (2)
- Arthritis (1)
- B cells (1)
- Cell activation (1)
- Complement receptor (1)
- Complement receptor 2 (1)
- Confocal microscopy (1)
- Corrosion inhibitors (1)
- Diselenide bridge (1)
- GC-FID/NPD (1)
- GC/MS (1)
- Indentation techniques (1)
- Interface (1)
- Mapping (1)
- Micro-mechanical properties (1)
- Primary long-chain alkyl amines (1)
- Proteasome maturation (1)
- Redox potential (1)
- Selenocysteine (1)
- Shedding (1)
- Stiffness (1)
- Synovial fluid (1)
- Tetramerisation (1)
- Type 2 diabetes mellitus (1)
- biorefineries (1)
- cellulose saccharification (1)
- high-sensitivity C-reactive protein (hsCRP) (1)
- homeostatic model assessment (HOMA) (1)
- intact proinsulin (1)
- lignocellulose chemistry (1)
- lignocellulosic raw material (1)
- oxalic acid (1)
- type 2 diabetes (1)
- type 2 diabetes mellitus (1)
Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP).
Methods: This cross-sectional study attempted to analyze the association of hsCRP levels with insulin resistance, β-cell dysfunction and macrovascular disease in 4270 non-insulin-treated patients with type 2 diabetes [2146 male, 2124 female; mean age ±SD, 63.9±11.1years; body mass index (BMI) 30.1±5.5kg/m2; disease duration 5.4±5.6years; hemoglobin A1c (HbA1c) 6.8±1.3%]. It consisted of a single morning visit with collection of a fasting blood sample. Observational parameters included several clinical scores and laboratory biomarkers.
Results: Stratification into cardiovascular risk groups according to hsCRP levels revealed that 934 patients had low risk (hsCRP <1mg/L), 1369 patients had intermediate risk (hsCRP 1–3mg/L), 1352 patients had high risk (hsCRP >3–10mg/L), and 610 patients had unspecific hsCRP elevation (>10mg/L). Increased hsCRP levels were associated with other indicators of diabetes-related cardiovascular risk (homeostatic model assessment, intact proinsulin, insulin, BMI, β-cell dysfunction, all p<0.001), but showed no correlation with disease duration or glucose control. The majority of the patients were treated with diet (34.1%; hsCRP levels 2.85±2.39mg/L) or metformin monotherapy (21.1%; 2.95±2.50mg/L hsCRP). The highest hsCRP levels were observed in patients treated with sulfonylurea (17.0%; 3.00±2.43mg/L).
Conclusions: Our results indicate that hsCRP may be used as a cardiovascular risk marker in patients with type 2 diabetes mellitus and should be evaluated in further prospective studies.
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus
(2006)